Literature DB >> 30116132

Liver transplantation from a live donor to a patient with maple syrup urine disease: Two case reports.

Ahmet Baştürk1, Meryem Keçeli1, Halil Erbiş2, Erdoğan Soyucen3, İbrahim Aliosmanoğlu2, Ayhan Dinçkan2, Aygen Yılmaz1, Reha Artan1.   

Abstract

Liver transplantation were reported in patients with classic maple syrup urine disease in the literature. Branched chain alpha keto acid dehydrogenase activity can be improved in patients after transplant, and a protein-restricted diet is usually not needed. The first patient was a boy aged 2,5 years who presented with frequent ketosis attacks and epileptic seizures, and the second patient was an 11-month-old boy who also presented with frequent ketosis episodes, both despite adherence to diet therapy. Both patients received liver transplantations from live donors. A low protein diet was no longer required and no decline in cognitive functions was observed in either patient in the follow-up. We wanted to present these cases to show that despite a normal diet, plasma levels of branched- chain amino acids remained normal without any decline in cognitive function after liver transplantation in patients with classic maple syrup urine disease patients.

Entities:  

Keywords:  Child; liver transplantation; maple syrup urine disease patients

Year:  2018        PMID: 30116132      PMCID: PMC6089790          DOI: 10.5152/TurkPediatriArs.2018.3710

Source DB:  PubMed          Journal:  Turk Pediatri Ars


  9 in total

1.  Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience.

Authors:  George V Mazariegos; D Holmes Morton; Rakesh Sindhi; Kyle Soltys; Navdeep Nayyar; Geoffrey Bond; Diana Shellmer; Benjamin Shneider; Jerry Vockley; Kevin A Strauss
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

2.  Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD.

Authors:  Björn Hoffmann; Christoph Helbling; Peter Schadewaldt; Udo Wendel
Journal:  Pediatr Res       Date:  2005-12-02       Impact factor: 3.756

3.  Trading places: liver transplantation as a treatment, not a cure, for metabolic liver disease.

Authors:  Benjamin L Shneider; Jerry Vockley; George V Mazariegos
Journal:  Liver Transpl       Date:  2011-06       Impact factor: 5.799

Review 4.  Liver transplantation for inherited metabolic disorders of the liver.

Authors:  Maryam Moini; Pramod Mistry; Michael L Schilsky
Journal:  Curr Opin Organ Transplant       Date:  2010-06       Impact factor: 2.640

Review 5.  Liver transplantation in maple syrup urine disease.

Authors:  U Wendel; J M Saudubray; A Bodner; P Schadewaldt
Journal:  Eur J Pediatr       Date:  1999-12       Impact factor: 3.183

6.  Elective liver transplantation for the treatment of classical maple syrup urine disease.

Authors:  K A Strauss; G V Mazariegos; R Sindhi; R Squires; D N Finegold; G Vockley; D L Robinson; C Hendrickson; M Virji; L Cropcho; E G Puffenberger; W McGhee; L M Seward; D H Morton
Journal:  Am J Transplant       Date:  2006-03       Impact factor: 8.086

7.  Acute Metabolic Crises in Maple Syrup Urine Disease After Liver Transplantation from a Related Heterozygous Living Donor.

Authors:  Aisha Al-Shamsi; Alastair Baker; Anil Dhawan; Jozef Hertecant
Journal:  JIMD Rep       Date:  2016-04-28

8.  Liver transplantation for classical maple syrup urine disease: long-term follow-up.

Authors:  Victoria M Díaz; Carmen Camarena; Ángela de la Vega; Mercedes Martínez-Pardo; Carmen Díaz; Manuel López; Francisco Hernández; Ane Andrés; Paloma Jara
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-11       Impact factor: 2.839

9.  A molecular model of human branched-chain amino acid metabolism.

Authors:  A Suryawan; J W Hawes; R A Harris; Y Shimomura; A E Jenkins; S M Hutson
Journal:  Am J Clin Nutr       Date:  1998-07       Impact factor: 7.045

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.